Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

Kato, Aki; Yasukawa, Tsutomu; Suga, Keiji; Hirano, Yoshio; Nozaki, Miho; Yoshida, Munenori; Ogura, Yuichiro

doi:10.1159/000368249

Cited by 6 publications

(6 citation statements)

References 24 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 According to Kato et al, mean BCVA in 36 eyes with AMD showed no significant change from 0.11 logMAR at treatment initiation to 0.12 logMAR after 3.3 injections over 12 months. 17 In this study, we treated 39 eyes with AMD. BCVA improved, ranging from −0.08 to 0.26 logMAR (mean 0.097), and from −0.08 to 0.40 logMAR at 12 months (mean 0.058, P =0.03), and was maintained at −0.08 to 0.52 logMAR at 24 months (mean 0.066, P =0.09), after a mean of 6.7±0.72 injections of aflibercept over 12 months and 4.8±1.8 injections from 13 to 24 months.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study

Sakamoto

Takahashi

Inoue

et al. 2018

OPTH

View full text Add to dashboard Cite

PurposeWe report the 2-year outcomes of intravitreal aflibercept (IVA) for exudative age-related macular degeneration (AMD) with good visual acuity (VA) and examine the baseline factors associated with good visual outcome.Materials and methodsThis multicenter, prospective study evaluated 39 eyes (39 AMD patients) enrolled from August 2013 to August 2014 at 12 and 24 months. Only patients with initial best-corrected VA (BCVA) >0.3 logarithm of the minimum angle of resolution (20/40 Snellen) were eligible. Three consecutive monthly IVA injections were followed by 2 monthly injections for 12 months. Thereafter, patients received injections on a treat- and-extend regimen for up to 24 months. Outcome measures included BCVA and central macular thickness (CMT) at 12 and 24 months. Post hoc analysis, BCVA, and CMT were evaluated by AMD types (typical AMD [tAMD], type 1, and type 2 polypoidal choroidal vasculopathy [PCV]). Baseline characteristics and BCVA associations were evaluated with linear regression analysis and Student’s t-test.ResultsMean age was 69 years and 26 of 39 eyes were male. tAMD, type 1 and type 2 PCV occurred in 18, 12, and 9 eyes, respectively. Baseline mean BCVA was 0.097 logarithm of the minimum angle of resolution (20/25 Snellen) and showed significant improvement to 0.058 (20/22 Snellen, P=0.03) at 12 months and 0.066 (20/23) at 24 months. CMT improved significantly from 320 (99) µm (mean [SD]) to 250 (93) µm (P=0.002) at 12 months and 240 (93) µm (P=0.0005) at 24 months. BCVA and CMT were not significantly different among the three groups. Only subretinal hemorrhage (SRH) was significantly associated with improved BCVA. BCVA change from baseline was −0.12 with SRH and −0.011 without SRH (P=0.017) at 12 months.ConclusionIVA showed good efficacy for exudative AMD with good VA at 24 months. tAMD and type 1 and 2 PCV showed similar prognosis. Baseline SRH predicted favorable long-term vision in AMD with good VA.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study

Sakamoto

Takahashi

Inoue

et al. 2018

OPTH

View full text Add to dashboard Cite

show abstract

“…There were 26 eyes (51.0%) with a logMAR BCVA of 0.15 or less (decimal BCVA of 0.7 or more) in the current study. In the majority of previous prospective studies, patients with a pretreatment decimal BCVA \ 0.5 were included [21], and there were only a few studies that treated patients with AMD including PCV that showed good BCVA [22,23]. Thus, the results of the current study may provide useful information with regard to IVA treatments of PCV patients in clinical practice.…”

Section: Discussionmentioning

confidence: 94%

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

et al. 2020

View full text Add to dashboard Cite

Introduction: To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-andextend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods: Fifty-one eyes of treatment-naïve PCV patients treated with IVA using a TAE regimen for at least 1 year were examined retrospectively. All patients received at least three IVA injections every 5 weeks, and the intervals were then extended by 2-week adjustments up to 13 weeks. When retinal exudation recurred, the patient was treated with the same regimen, but with a shortened interval of 5 weeks.The main outcome measures were changes in bestcorrected visual acuity (BCVA) and central retinal thickness (CRT) as well as the treatment interval at 1 year. Results: The mean logarithm of the minimum angle of resolution BCVA improved from 0.24 ± 0.32 at baseline to 0.18 ± 0.31 at 12 months (p = 0.048). The mean CRT decreased from 350.3 ± 147.7 lm at baseline to 215.3 ± 75.0 lm at 4 months (p \ 0.001), after which it was maintained at this level. At 12 months, the administration interval was 5 weeks in eight eyes (15.7%), 7 weeks in six eyes (11.8%), 9 weeks in two eyes (3.9%), 11 weeks in four eyes (7.8%), and 13 weeks in 31 eyes (60.8%). Female sex, a thinner CRT at 6 months, and absence of polypoidal lesions at 12 months were significant factors related to patients whose treatment intervals could be extended without recurrence to 13 weeks. Conclusion: IVA using a TAE regimen improved visual and anatomical outcomes in eyes with PCV at 1 year using a protocol to adjust the injection intervals specifically for each patient so as to obtain no retinal exudation.

show abstract

“…Mori et al [36] performed an average of 4.7 injections of intravitreal ranizbizumab in 50 PCV eyes with a baseline BCVA of 0.6 to 1.0, and reported a significant improvement in BCVA from the baseline (0.11 log-MAR) to 12 months (0.07 logMAR). Kato et al [37] administered intravitreal ranibizumab in PCV with baseline BCVA of 0.10 logMAR. With 3.05 injections, the absolute value of visual acuity improved to 0.09, but there was no statistical significance.…”

Section: Discussionmentioning

confidence: 99%

“…The size of lesions would be smaller, the activity of the disease would be less severe, damaged retinal tissues that cannot be recovered would be less prevalent in eyes with good visual acuity, and so, the final vision would be better. Table 3 summarizes the BCVA change at 12 months after intravitreal anti-VEGF treatment of previous studies and current study [20,[34][35][36][37][38][39]41].…”

Section: Discussionmentioning

confidence: 99%

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity

Kwon

Pak

Lee

et al. 2021

Korean J Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. Methods This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naïve PCV were retrospectively reviewed. Patients with an initial BCVA of 20 / 40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with three consecutive monthly injections, followed by pro re nata regimen according to the clinician’s discretion at variable interval visits. The proportions of eyes for which BCVA was maintained (≤ 0.2 logarithm of the minimum angle of resolution change) or improved at 12 months were evaluated. The changes of BCVA, central subfield macular thickness (CSMT), pigment epithelial detachment, and subretinal fluid also were assessed. Results A total of 86 eyes were included. The mean number of injections for 12 months of treatment was 5.4 ± 1.7. BCVA was maintained or improved in 94.2% (81 / 86) of cases. Mean BCVA (logarithm of the minimum angle of resolution) had changed from the baseline (0.23 ± 0.09) at 3 months (0.21 ± 0.14), 6 months (0.24 ± 0.22), and 12 months (0.20 ± 0.18), but with no statistical significance. CSMT had improved significantly from the baseline (336.1 ± 97.3 μm) at 3 months (223.6 ± 47.22 μm), 6 months (239.6 ± 64.2 μm), and 12 months (223.8 ± 47.9 μm). Pigment epithelial detachment was observed in 93% of cases at the baseline, 72.1% at 3 months, and 69.8% at 12 months, showing a significant decrease at all observation points. Subretinal fluid was observed in 91.9% of cases at the baseline, 20.9% at 3 months, and 29.1% at 12 months, showing a significant decrease at all observation points. Conclusions In cases of PCV with good visual acuity, intravitreal aflibercept injections decreased CSMT and were effective in maintaining visual acuity.

show abstract

Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

Cited by 6 publications

References 24 publications

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity

Contact Info

Product

Resources

About